The recently expanded approval of some TNF‑α blockers for the treatment of moderate to severe psoriasis in pregnancy has facilitated therapy of this group of patients with approved drugs. To date, there are no evidence-based structured therapy recommendations for these psoriasis patients with the result that the uncertainties of the treating physicians usually lead to individual decisions. On the basis of our clinical experience and the currently valid approval for systemic therapeutics, we have developed a therapy algorithm that enables an interdisciplinary, structured approach to counseling and supporting pregnant women with psoriasis, which makes decision-making for colleagues in other disciplines, in particular gynecology, transparent.
Keywords: Biologicals; Immunomodulation; Label conform; Pregnant women; Safety.